Today's guest is Matthew Greving, VP of Machine Learning and Platform Technologies at iBio. Founded in 2008, iBio envision a world where drug discovery is not left to chance but guided by AI to make therapeutic development smarter, more precise and ultimately faster.  They are using iBio’s Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. 

Matt is the mastermind behind iBio’s technology platform and oversees the development of iBio’s tech stack. He is driven by a passion to utilize the power of integrated computation and laboratory discovery to solve difficult problems in human health.  Before iBio, Matthew co-founded RubrYc Therapeutics to pursue this passion and act on his belief that we are at the very early stage of computation-laboratory integration in biological discovery.  

In today's episode, Matthew will talk about:

His background and journey to now,

Advancing antibody therapies for challenging, unexplored drug targets,

Utilizing an AI-engineered approach for successful antibody therapeutics development,

Seeking talent bridging computation and biochemical drug discovery,

Leveraging multimodal data for transformative drug discovery impact,

What he looks for when hiring into his team,

What makes iBio a great place to work